Home Newsfeeds Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5

Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5

Cowen & Co. analyst Ritu Baral downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Market Perform and raises the price target from $67 to $68.5.

byBenzinga Newsdesk

August 9, 2022

1 minute read

Cowen & Co. analyst Ritu Baral downgrades Global Blood Therapeutics (NASDAQ:GBT) from Outperform to Market Perform and raises the price target from $67 to $68.5.

Truist Securities Maintains Buy on Expedia Group, Lowers Price Target to $175

By Benzinga Newsdesk

October 28, 8:39 AM

Truist Securities analyst Naved Khan maintains Expedia Group (NASDAQ:EXPE) with a Buy and lowers the price target from $185 to $175.

EXPE

Morgan Stanley Maintains Equal-Weight on Regency Centers, Lowers Price Target to $57.5

By Benzinga Newsdesk

July 15, 12:06 PM

Morgan Stanley analyst Richard Hill maintains Regency Centers (NASDAQ:REG) with a Equal-Weight and lowers the price target from $63 to $57.5.

REG

Nike Set To Report Earnings Thursday — Options Market Implies 6% Move

By Priya Nigam

September 28, 9:08 AM

NIKE, Inc (NYSE: NKE) is expected to report financial results for its first quarter, after the closing bell on Sept. 28, 2023.

NKE

Why Clearmind Medicine Shares Are Nosediving

By Henry Khederian

April 4, 11:52 AM

Clearmind Medicine Inc (NASDAQ: CMND) shares are trading lower by 60.1% to $0.57 Tuesday morning after the company announced a $3.5 million public offering priced at $0.78 per share. The offering is expected to close on April 6, subject to the satisfaction of customary closing conditions.

CMND

Cowen & Co. Downgrades Global Blood Therapeutics to Market Perform, Raises Price Target to $68.5

Related Posts

Truist Securities Maintains Buy on Expedia Group, Lowers Price Target to $175

Morgan Stanley Maintains Equal-Weight on Regency Centers, Lowers Price Target to $57.5

Nike Set To Report Earnings Thursday — Options Market Implies 6% Move

Why Clearmind Medicine Shares Are Nosediving